
    
      This is a randomized, double-blind, placebo-controlled, Phase 3 trial to evaluate QPI-1002
      versus placebo for the prevention of Major Adverse Kidney Events in subjects at high risk for
      acute kidney injury following cardiac surgery. Subjects will be dosed with active drug or
      placebo after the completion of cardiovascular surgery.
    
  